Y mAbs Therapeutics

Yahoo Finance • 4 days ago

Y-mAbs Therapeutics’ SWOT analysis: acquisition shakes up oncology stock outlook

Y-mAbs Therapeutics, Inc., a biopharmaceutical company focused on developing innovative antibody-based cancer therapies, has recently become the subject of significant market attention. The company, known for its FDA-approved drug Danyelza... Full story

Yahoo Finance • 9 days ago

The trading volume of these stocks is deviating from the norm in today's session.

Volume analysis on 2025-08-08: stocks with an unusual volume in today's session. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/stock/quote/SGBX/profile] 46.49% Today's trading... Full story

Yahoo Finance • 9 days ago

Y mAbs Therapeutics earnings beat by $0.19, revenue topped estimates

Investing.com - Y mAbs Therapeutics (NASDAQ: YMAB) reported second quarter EPS of $-0.07, $0.19 better than the analyst estimate of $-0.26. Revenue for the quarter came in at $19.53M versus the consensus estimate of $18.37M. Y mAbs Ther... Full story

Yahoo Finance • 9 days ago

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; tra... Full story

Yahoo Finance • 10 days ago

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based ther... Full story

Yahoo Finance • 11 days ago

Unusual volume stocks are being observed in Wednesday's session.

Discover the stocks with unexpected trading volume in today's session on the US markets. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT TNON [https://www.chartmill.com/stock/quote/TNON/profile] 7.14% The... Full story

Yahoo Finance • 12 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, YMAB, BASE, CORZ on Behalf of Shareholders

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 12 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB), Couchbase, Inc. (Nasdaq – BASE), Core Scientific, Inc. (Nasdaq - CORZ)

BALA CYNWYD, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 26 days ago

Leptomeningeal Metastases Market Research Report 2025-2035 | Competitive Analysis of Plus Therapeutics, AstraZeneca, AngioChem, and Y-mAbs Therapeutics

Company Logo Leptomeningeal metastases (LM), the spread of cancer to the brain's and spinal cord's protective tissues, pose severe challenges, stemming from cancers like breast and lung. Rising cancer survival rates have increased LM inci... Full story

Yahoo Finance • last month

Y-mAbs Therapeutics announces results of annual shareholder meeting votes

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a biotechnology company with a market capitalization of $192 million and a strong financial health rating according to InvestingPro, held its annual meeting of stockholders on Friday, July 11, where... Full story

Yahoo Finance • 2 months ago

Y-mAbs Therapeutics' SWOT analysis: oncology biotech stock faces growth hurdles

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a market capitalization of $213.34 million, is navigating a complex landscape in the oncology therapeutics market. The company, known for its focus... Full story

Yahoo Finance • 3 months ago

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

Company’s Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugat... Full story

Yahoo Finance • 3 months ago

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunothe... Full story

Yahoo Finance • 3 months ago

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunothe... Full story

Yahoo Finance • 3 months ago

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated t... Full story

Yahoo Finance • 3 months ago

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunothe... Full story

Yahoo Finance • 3 months ago

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunothe... Full story

Yahoo Finance • 4 months ago

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy... Full story

Yahoo Finance • 5 months ago

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceut... Full story

Yahoo Finance • 6 months ago

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy... Full story